A Rugged, Reliable, Portable, Safe, and Simple Naloxone HCl Auto-Injector forLife-Saving Treatment of Opioid Overdose

NIH RePORTER · NIH · R43 · $55,000 · view on reporter.nih.gov ↗

Abstract

Project Abstract 136 people die each day from opioid overdose in the US. Naloxone has significantly decreased opioid mortality as a first line life-saving measure, and often it is being administered by untrained medical personnel under situations of extreme stress—which studies show leads to accidents, missed doses and tragic consequences. Pirouette has designed a novel, low-cost, and intuitive auto-injector called REZQGO that anyone could use to deliver lifesaving Naloxone safely and quickly during an opioid overdose; this Phase I project supplement will assist Pirouette in market research, regulatory planning, pricing / reimbursement strategy, usability, and the commercialization / GMP implementation of the REZQGO product lineup. Pirouete Medical Inc. Confiden�al

Key facts

NIH application ID
10987197
Project number
3R43DA059474-01S1
Recipient
PIROUETTE MEDICAL
Principal Investigator
Conor R Cullinane
Activity code
R43
Funding institute
NIH
Fiscal year
2024
Award amount
$55,000
Award type
3
Project period
2024-02-01 → 2024-07-31